Lifecare is happy to announce that the collaboration with the Chemistry
Department of Bath University, UK, has been prolonged and further amplified.
This will ensure mutual beneficiary progress on the development of proprietary
specific chemistry solutions for detection of glucose and additional analytes of
interest based on the Sencell technology.
In addition, Lifecare has directly engaged, Dr. Jordan Edward Gardiner as a
consultant. Dr. Jordan Edward Gardiner is the scientist responsible for the
Lifecare developments at Bath University under the guidance of Prof. Tony James,
a worldwide leading expert in organic sensor chemistry development.
The collaboration between Lifecare and Prof. Tony James research group has so
far resulted in significant improvements in sensitivity and specificity of the
chemistry composition for glucose detection used in Lifecares core and
proprietary Sencell technology for diabetes management.
The European Patent Office recently communicated its intention to issue a new
patent for Lifecares improved system for the osmotic pressure based Sencell
technology (https://newsweb.oslobors.no/message/528774). The expected patent
will increase the scope of protection until 2038 and broaden the technology
scope to include detection of several parameters in the interstitial fluid.
Based on the prolonged and amplified collaboration, Lifecare expect to develop
effective chemical compositions suitable for exploiting additional commercial
opportunities for the Sencell technology, in addition to the core field of
“With this step, we ensure that the scope of Lifecares Sencell sensor
development expands from glucose alone to other analytes, such as but not
limited to lactate, fructose, and calcium”, says Joacim Holter Lifecare’s CEO.
“This will help to collect complementary information for understanding the
user’s metabolism and ultimately providing personalized guidance to maintain
better glucose control and improve general health”.
This is Lifecare
Lifecare (LIFE) is a Bergen-based technology company developing a miniaturized
implantable long-term sensor for correct and continuous monitoring of blood
sugar in people with diabetes. The company’s patented technology also has the
potential for use in various biomarkers.
For further information, please contact:
Joacim Holter, CEO, Lifecare AS, email@example.com +47 40 05 90 40
This stock exchange announcement was published by Kine Hereid, Investor
Relations at Lifecare AS, on 22 June, 2021 at 08:15 CET.